Innovent Biologics, Inc. (1801.HK)

37,400 +0,600 (+1,63%) Alla chiusura: 04:08PM HKT

Innovent Biologics, Inc.

168 Dongping Street
Suzhou Industrial Park
Suzhou 215123
China
86 512 6956 6088
https://www.innoventbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 4.872

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. De-Chao Yu Ph.D.	Co-Founder, Chairman & CEO	39,16M	N/D	1964
Mr. Hao Xi Ede	Executive Director & Fund Managing Partner	7,63M	N/D	1959
Dr. Yong Jun Liu M.D., Ph.D.	President	N/D	N/D	1969
Ms. Fei You	Chief Financial Officer	N/D	N/D	1979
Ms. Vivian Zhang	Chief People Officer, GM & Executive Director	N/D	N/D	1987
Mr. Min Liu	Chief Commercial Officer	N/D	N/D	N/D
Mr. Dongming Wang	Senior Vice President	N/D	N/D	N/D
Mr. Blake Salisbury	Senior Vice President	N/D	N/D	N/D
Dr. Hui Zhou Ph.D.	Senior Vice President	N/D	N/D	N/D
Dr. Nageatte Ibrahim M.D.	Oncology Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Governance aziendale

L'ISS Governance QualityScore di Innovent Biologics, Inc. al 29 giugno 2024 è 10. I criteri di valutazione fondamentali sono revisione: 3; Consiglio di Amministrazione: 4; diritti degli azionisti: 7; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.